دورية أكاديمية
Feasibility of monitoring Global Breast Cancer Initiative Framework key performance indicators in 21 Asian National Cancer Centers Alliance member countries.
| العنوان: | Feasibility of monitoring Global Breast Cancer Initiative Framework key performance indicators in 21 Asian National Cancer Centers Alliance member countries. |
|---|---|
| المؤلفون: | Ong SK; PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Brunei Darussalam., Haruyama R; Bureau of International Health Cooperation, National Center for Global Health and Medicine, Japan., Yip CH; Faculty of Medicine, University of Malaya, Malaysia., Ngan TT; Center for Population Health Sciences, Hanoi University of Public Health, Hanoi, Vietnam.; Centre for Public Health, Queen's University Belfast, United Kingdom., Li J; Women's Health and Genetics, Genome Institute of Singapore, A∗Star, Singapore., Lai D; School of Digital Science, Universiti Brunei Darussalam, Brunei Darussalam., Zhang Y; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China., Yi S; KHANA Center for Population Health Research, Phnom Penh, Cambodia.; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore., Shankar A; Department of Radiation Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi, India., Suzanna E; National Cancer Center Indonesia, Dharmais Cancer Hospital, Jakarta, Indonesia., Jung SY; Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea., Ho PJ; Women's Health and Genetics, Genome Institute of Singapore, A∗Star, Singapore., Yusuf A; Shaukat Khanum Memorial Cancer Hospital and Research Centres, Lahore and Peshawar, Pakistan., Nessa A; Department of Gynaecological Oncology, Bangabandhu Sheikh Mujib Medical University, Bangladesh., Jung KW; National Cancer Centre Graduate School of Cancer Science and Policy, Goyang, Republic of Korea., Fernando E; National Cancer Control Programme, Ministry of Health, Sri Lanka., Baral S; Bhaktapur Cancer Hospital, Bhaktapur, Nepal., Bagherian M; Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran., Pradhan P; Jigme Dorji Wangchuck National Referral Hospital, Bhutan., Jugder U; Cancer Registry-surveillance and Early Detection Division, National Cancer Center of Mongolia, Ulaanbaatar, Mongolia., Vongdala C; Cancer Center, Mittaphab Hospital, Vientiane, Lao PDR., Yusof SN; National Cancer Institute, Putrajaya, Malaysia., Thiri K; Pink Rose Breast Cancer Patients Support Group, Yangon, Myanmar., Sripan P; Research Institute for Health Sciences, Chiang Mai University, Thailand., Cairo C; Department of Health, Disease Prevention and Control Bureau, Manila, Philippines., Matsuda T; National Cancer Center Institute for Cancer Control, Tokyo, Japan., Sangrajran S; National Cancer Institute, Bangkok, Thailand., Kiak-Mien Tan V; National Cancer Centre Singapore, Singapore., Mehrotra R; Indian Cancer Genome Atlas, India & Centre for Health, Innovation and Policy Foundation, India., Anderson BO; World Health Organisation (WHO), Geneva, Switzerland. |
| المصدر: | EClinicalMedicine [EClinicalMedicine] 2023 Dec 16; Vol. 67, pp. 102365. Date of Electronic Publication: 2023 Dec 16 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : The Lancet, [2018]- |
| مستخلص: | Background: The Global Breast Cancer Initiative (GBCI) Framework, launched by the World Health Organisation (WHO) in 2023, emphasises assessing, strengthening, and scaling up services for the early detection and management of breast cancer. This study aims to determine the feasibility of monitoring the status of breast cancer control in the 21 Asian National Cancer Centers Alliance (ANCCA) countries based on the three GBCI Framework key performance indicators (KPIs): stage at diagnosis, time to diagnosis, and treatment completion. Methods: We reviewed published literature on breast cancer control among 21 ANCCA countries from May to July 2023 to establish data availability and compiled the latest descriptive statistics and sources of the indicators using a standardised data collection form. We performed bivariate Pearson's correlation analysis to measure the strength of correlation between stage at diagnosis, mortality and survival rates, and universal health coverage. Findings: Only 12 (57%) ANCCA member countries published national cancer registry reports on breast cancer age-standardised incidence rate (ASIR) and age-standardised mortality rate (ASMR). Indonesia, Myanmar, and Nepal had provincial data and others relied on WHO's Global Cancer Observatory (GLOBOCAN) estimates. GLOBOCAN data differed from the reported national statistics by 5-10% in Bhutan, Indonesia, Iran, the Republic of Korea, Singapore, and Thailand and >10% in China, India, Malaysia, Mongolia, and Sri Lanka. The proportion of patients diagnosed in stages I and II strongly correlated with the five-year survival rate and with the universal health coverage (UHC) index. Three countries (14%) reported national data with >60% of invasive breast cancer patients diagnosed at stages I and II, and a five-year survival rate of >80%. Over 60% of the ANCCA countries had no published national data on breast cancer staging, the time interval from presentation to diagnosis, and diagnosis to treatment. Five (24%) countries reported data on treatment completion. The definition of delayed diagnosis and treatment completion varied across countries. Interpretation: GBCI's Pillar 1 KPI correlates strongly with five-year survival rate and with the UHC index. Most ANCCA countries lacked national data on cancer staging, timely diagnosis, and treatment completion KPIs. While institutional-level data were available in some countries, they may not represent the nationwide status. Strengthening cancer surveillance is crucial for effective breast cancer control. The GBCI Framework indicators warrant more detailed definitions for standardised data collection. Surrogate indicators which are measurable and manageable in country-specific settings, could be considered for monitoring GBCI indicators. Ensuring UHC and addressing health inequalities are essential to early diagnosis and treatment of breast cancer. Funding: Funding for this research article's processing fee (APC) will be provided by the affiliated institution to support the open-access publication of this work. The funding body is not involved in the study design; collection, management, analysis and interpretation of data; or the decision to submit for publication. The funding body will be informed of any planned publications, and documentation provided. Competing Interests: The authors have no conflicts of interest to declare. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of their affiliated institutions. Where authors are identified as personnel of the World Health Organisation (WHO), the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the WHO. Where maps are concerned, all rights are reserved by the WHO. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement. (© 2023 Published by Elsevier Ltd.) |
| References: | World J Clin Oncol. 2022 Mar 24;13(3):209-218. (PMID: 35433294) Lancet. 2017 Sep 16;390(10100):1151-1210. (PMID: 28919116) Cancer Treat Rev. 2022 Mar;104:102339. (PMID: 35074727) Prev Med. 2021 Oct;151:106585. (PMID: 34217412) Eur J Cancer. 2017 Mar;74:26-37. (PMID: 28335885) BMJ. 2023 Jun 13;381:e074684. (PMID: 37311588) Lancet. 2018 Mar 17;391(10125):1023-1075. (PMID: 29395269) Ann Acad Med Singap. 2015 Sep;44(9):317-25. (PMID: 26584660) Breast. 2022 Dec;66:15-23. (PMID: 36084384) BMJ. 2021 Feb 24;372:n256. (PMID: 33627312) Ann Acad Med Singap. 2022 Aug;51(8):493-501. (PMID: 36047524) CA Cancer J Clin. 2017 Mar;67(2):93-99. (PMID: 28094848) N Engl J Med. 2015 Jun 11;372(24):2353-8. (PMID: 26039523) Sci Rep. 2022 Nov 7;12(1):18915. (PMID: 36344740) Int J Environ Res Public Health. 2020 Jun 05;17(11):. (PMID: 32517042) Cancer Biol Med. 2021 May 18;:. (PMID: 34002584) Lancet Reg Health West Pac. 2023 Aug 01;39:100860. (PMID: 37576906) Curr Oncol. 2023 Jan 21;30(2):1461-1472. (PMID: 36826073) Int J Environ Res Public Health. 2021 Nov 23;18(23):. (PMID: 34886015) Asian Pac J Cancer Prev. 2021 Oct 01;22(10):3081-3092. (PMID: 34710982) Nat Med. 2022 Dec;28(12):2563-2572. (PMID: 36404355) BMC Cancer. 2020 Nov 10;20(1):1080. (PMID: 33167930) Lancet. 1999 Apr 3;353(9159):1119-26. (PMID: 10209974) Cancers (Basel). 2022 Aug 30;14(17):. (PMID: 36077752) Am J Trop Med Hyg. 2017 Nov;97(5):1461-1468. (PMID: 29016331) Lancet Oncol. 2021 Nov;22(11):1632-1642. (PMID: 34653370) BMC Public Health. 2016 Aug 08;16:738. (PMID: 27502284) Lancet Oncol. 2014 Jun;15(7):e279-89. (PMID: 24872111) World J Surg. 2014 Jul;38(7):1676-84. (PMID: 24280975) JAMA. 2009 Oct 7;302(13):1429-36. (PMID: 19809024) PLoS One. 2023 Jul 5;18(7):e0288073. (PMID: 37406000) Lancet Oncol. 2022 Jun;23(6):729-738. (PMID: 35550274) Cancer Med. 2020 Apr;9(7):2435-2444. (PMID: 32053293) BMC Cancer. 2014 Mar 20;14:212. (PMID: 24650245) |
| معلومات مُعتمدة: | 001 International WHO_ World Health Organization |
| فهرسة مساهمة: | Keywords: ANCCA; Asia; Breast cancer; Cancer stage; Completion of treatment; Early diagnosis; Feasibility; Indicators; Screening; Survival; WHO GBCI Framework |
| تواريخ الأحداث: | Date Created: 20231221 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC10731600 |
| DOI: | 10.1016/j.eclinm.2023.102365 |
| PMID: | 38125964 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2589-5370 |
|---|---|
| DOI: | 10.1016/j.eclinm.2023.102365 |